Status:
RECRUITING
The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Conditions:
Thrombosis, Venous
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC...
Detailed Description
Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
- CRC patients with VTE treated with an anticoagulant for at least 3 moths.
Exclusion
- Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
327 Patients enrolled
Trial Details
Trial ID
NCT06998745
Start Date
May 1 2025
End Date
December 30 2027
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 5106555